Last reviewed · How we verify
ATG-LDPTCy
ATG-LDPTCy is an immunosuppressive agent that targets the T-cell receptor.
ATG-LDPTCy is an immunosuppressive agent that targets the T-cell receptor. Used for Prevention of transplant rejection.
At a glance
| Generic name | ATG-LDPTCy |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | Immunosuppressant |
| Target | T-cell receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
ATG-LDPTCy works by binding to the T-cell receptor, thereby inhibiting T-cell activation and proliferation. This mechanism is crucial in preventing transplant rejection and treating certain autoimmune disorders.
Approved indications
- Prevention of transplant rejection
Common side effects
- Thrombocytopenia
- Leukopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |